OXY GENE
Live / Registered — Registered (as of 16 Nov 2021)
What this means for you
Registered since 16 Nov 2021. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 16 Nov 2027: the §71 affidavit of use).
Record
- Serial number
- 79280862
- Registration number
- 6557311
- Mark type
- Design + words
- Filed
- 15 Jan 2020
- Published for opposition
- 31 Aug 2021
- Registered
- 16 Nov 2021
- Next maintenance filing
- §71 affidavit of use, due by 16 Nov 2027 (grace period to 16 May 2028)
- Attorney of record
- Monte L. Falcoff/Jessica S. Sachs
Goods and services
- Class 040 — Treatment of materials: Supply in the nature of custom manufacture of production units for biological molecules, particularly viral vectors and monoclonal antibodies, in the pharmaceutical and biopharmaceutical field; contract manufacturing for others of biological molecules, particularly viral vectors and monoclonal antibodies, in the pharmaceutical and biopharmaceutical field; production in the nature of custom manufacture of biological molecules, particularly viral vectors and monoclonal antibodies, in the pharmaceutical and biopharmaceutical field; none of the foregoing in the field of cancer research or for cancer therapies or vascular targeting agents
- Class 042 — Scientific and technological services: Study in the nature of conducting scientific feasibility studies and design of production factories and buildings; inspection of production factories and buildings for quality control and consultancy purposes; engineering; preparation of technical studies; quality control of production units in the pharmaceutical and biopharmaceutical field with a view to certification; research and development of new products for third parties; technological services regarding manufacture of biological molecules, particularly viral vectors and monoclonal antibodies, in the pharmaceutical and biopharmaceutical field; none of the foregoing in the field of cancer research or for cancer therapies or vascular targeting agents
Owner
- HENOGEN, B-6041 Gosselies, BE
- HENOGEN, B-6041 Gosselies, BE
- HENOGEN, B-6041 Gosselies, BE
- NOVASEP PROCESS, F-54340 POMPEY, FR
Board proceedings on this mark
- Ex Parte Appeal No. 79280862 — Novasep Process, filed 19 Jan 2021 (Terminated)
The owner also pleads this mark in 1 other Board proceeding.
Prosecution history
- 20 Aug 2026 — NEW REPRESENTATIVE AT IB RECEIVED
- 04 May 2024 — NEW REPRESENTATIVE AT IB RECEIVED
- 23 May 2022 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 03 May 2022 — FINAL DISPOSITION NOTICE SENT TO IB
- 03 May 2022 — FINAL DISPOSITION PROCESSED
- 16 Feb 2022 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 16 Nov 2021 — REGISTERED-PRINCIPAL REGISTER
- 31 Aug 2021 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 31 Aug 2021 — PUBLISHED FOR OPPOSITION
- 29 Aug 2021 — NOTIFICATION PROCESSED BY IB
- 23 Aug 2021 — ASSIGNED TO EXAMINER
- 11 Aug 2021 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 11 Aug 2021 — NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
- 11 Aug 2021 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 25 Jul 2021 — EXPARTE APPEAL TERMINATED